NORD writes PhRMA
National Organization for Rare Disorders criticizes Pharmaceutical Research & Manufacturers of America for ads suggesting that without drug patents research on rare diseases would decline. "The exclusivity provision of the Orphan Drug Act precludes competition for seven years with a higher degree of certainty [than patents], and this has influenced hundreds of companies to invest in orphan drug research and development," NORD says in June 6 letter...
You may also be interested in...
Guidance discusses what are generically called virtual inspections, but which the agency terms “remote interactive evaluations.” As site inspections remain constrained by the pandemic, remote interactive evaluations “should help FDA operate within normal timeframes,” the document says.
At Repro-Med, James Beck has been replaced by Linda Tharby as CEO, and more.
Norway’s Pre Diagnostics uses the intracellular approach to neurodegenerative disease diagnosis. It believes its technology will open up a world of precision medicine for Alzheimer’s disease patients.